Investors

News Release

<< Back
Codexis Selected for Third Presidential Green Chemistry Award in Seven Years

Development of Biocatalytic Process to Manufacture Simvastatin Recognized by EPA

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 18, 2012-- Codexis, Inc. (Nasdaq:CDXS) today announced it has been awarded the annual Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) for the development of an efficient biocatalytic process to manufacture simvastatin, a leading drug for treating high cholesterol. This marks the third time in seven years that Codexis has been honored with this award; Codexis was a recipient in 2006 and 2010.

Simvastatin is the most prescribed statin in the U.S., with 94.1 million prescriptions in 2010 according to IMS Health. Traditionally, synthesis of simvastatin has required an inefficient, multistep chemical process that involves significant quantities of hazardous reagents. In collaboration with Professor Yi Tang at the University of California, Los Angeles, Codexis conceived and developed a synthesis using an engineered enzyme and a practical, low-cost feedstock. Codexis optimized both the enzyme and the chemical process for the large-scale, commercial manufacture of simvastatin. The resulting process produces high quality simvastatin in a cost–effective manner and greatly reduces the use of hazardous chemicals and the amount of waste produced.

“Collaborating with the Codexis team was a true inspiration. Their directed evolution technology empowered us to go beyond academic theory and deliver a more environmentally friendly process that is impacting the pharmaceutical industry today,” said Yi Tang, Professor, University of California Los Angeles.

“Green chemistry and Codexis’ CodeEvolver™ directed evolution technology represent the future of cleaner, more efficient, and cost-advantaged pharmaceutical manufacturing processes. With the help of Professor Tang and his team, this award confirms Codexis’ role as an industry leader, and we are honored to be recognized for a third time by the EPA for our achievements,” said Gjalt Huisman, Ph.D., Vice President of Product Planning, Pharmaceuticals at Codexis.

The process was scaled up at Codexis’ longstanding collaborator, Arch Pharmalabs Ltd., in Mumbai, India. Arch Pharmalabs manufactures a number of products for Codexis, including the 2006 Presidential Green Chemistry Challenge Award-winning process for atorvastatin, the active ingredient in Pfizer’s Lipitor®.

“We are running six biocatalytic processes developed by Codexis and have shown that they are reliably scalable and comparable to chemical processes, while offering significant advantages in terms of product purity, reduced waste, and reduced energy consumption,” said Dr. Ganesh Pai, Director of Research and Development, Arch Pharmalabs Ltd.

Codexis is the first and, to date, only company to have won the Presidential Green Chemistry Challenge Award in both the small business and open categories. In 2010, in collaboration with Merck, Codexis won a previous Green Chemistry award for the development of a novel biocatalytic method for the synthesis of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia®. And in 2006, as a small business with less than $40 million in annual sales, Codexis was similarly honored for developing three enzymes used to produce the key chiral building block for atorvostatin.

About Presidential Green Chemistry Challenge Awards Program

The Presidential Green Chemistry Challenge Awards are presented annually by the Environmental Protection Agency to recognize new technologies that help prevent pollution by reducing or eliminating hazardous waste in industrial production. It provides recognition of outstanding chemical technologies that incorporate the principles of green chemistry into chemical design, manufacture, and use, and that have been or can be utilized by industry in achieving their pollution prevention goals. The award was launched in 1995 in partnership with the chemical industry, the American Chemical Society, the National Academies and other stakeholders.

About Codexis, Inc.

Codexis, Inc. is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates. Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.

Source: Codexis, Inc.

Codexis, Inc.
Kelly McAlearney, 415-503-4073 (Media)
media@codexis.com
212-362-1200 (Investors)
ir@codexis.com

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS |

Share Page

X
| E-mail Alerts E-mail Alerts | IR Contacts Contacts | Financial Tear Sheet Tear Sheet

WE ARE BIOCATALYSISTM

We are an industrial biotechnology company delivering real business results through biobased innovation in chemicals, fuels, pharmaceuticals, consumer, and industrial products.

PHARMACEUTICAL ENZYMES


Supporting faster, cleaner, more efficient pharmaceutical manufacturing processes

Codexis delivers a range of chemicals at kilogram to multi-ton scale, through a partnered manufacturing network

CODEXIS

WHAT WE DO


Codexis delivers revolutionary biocatalytic routes that no one else can


CODEXIS

MEDIA CENTER


Visit our Media Center for the latest product information, videos, imagery, technical papers and press information.


CAREERS AT CODEXIS

An opportunity to make a difference.

Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do


CODEXIS

INVESTOR CENTER


Access to Codexis information
for the investment community

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue